Clinical trial NCT00333437: Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Official title: Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Scleroderma, Systemic
Keywords: Scleroderma, Systemic
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2006-06-05
Enrollment: 7
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

Detailed description: The proposed study is designed to evaluate the safety and efficacy of mycophenolate mofetil (CellCept) for the treatment of symptomatic pulmonary alveolitis due to systemic sclerosis (SSc). This study utilizes a prospective, open-label, experimental design.

Primary Hypothesis: The alveolitis in patients with SSc, as defined by decreased forced vital capacity (FVC), bronchoalveolar lavage (BAL), and High Resolution Chest Tomography (HRCT) is responsive to 1 year of daily mycophenolate mofetil therapy.

Secondary Hypothesis: Quality of life, six-minute walk and single-breath diffusing capacity for carbon monoxide (DLCO) improve in patients with SSc mediated alveolitis after therapy with mycophenolate mofetil. This response to therapy is associated with a change in the inflammatory cytokine profile present in BAL fluid.

Eligibility criteria: Inclusion Criteria:

* To participate in this study, patients must first undergo a BAL and HRCT. To be eligible to undergo HRCT and BAL (under the purview of this trial), prospective patients must meet the following criteria:

  * Aged 21-70.
  * Negative pregnancy test (with a sensitivity of at least 50 mIU/mL) for females of child-bearing potential
  * All patients must fulfill the criteria for SSc by American College of Rheumatology (ACR) criteria (Subcommittee for Scleroderma Criteria 1980).
  * FVC \< 85% of predicted.
  * SSc for no more than 7 years with onset defined as the date of the first non-Raynaud manifestation.
  * Patients may have limited (cutaneous thickening distal but not proximal to elbows and knees, with or without facial involvement) or diffuse (cutaneous thickening proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc (Medsger 1995).
  * Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.
* To be eligible to take study medication, the patient must meet not only the criteria above, but also must have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils in screening BAL fluid and/or ground glass opacification on HRCT.
* Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 1 week before beginning therapy. CellCept therapy will not be initiated until a report of a negative pregnancy test has been obtained.
* Effective contraception must be used before beginning CellCept therapy, during therapy, and for 6 weeks following discontinuation of therapy, even where there has been a history of infertility, unless due to hysterectomy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy does occur during treatment, the physician and patient should discuss the desirability of continuing the pregnancy.

Exclusion Criteria:

* FVC \< 45% of predicted or DLCO (corrected for hemoglobin \[Hgb\] but not for alveolar volume) \< 35% of predicted (suggestive of severe, probably irreparable, disease).
* Leukopenia (white blood cell count \< 4000) or thrombocytopenia (platelet count \< 100,000).
* Serum creatinine ≥ 2.0 mg/dl.
* Pregnancy, breast feeding, unreliability, drug abuse, or chronic debilitating disease.
* Uncontrolled congestive heart failure.
* Active infection of the lung, or elsewhere, whose management would be compromised by mycophenolate mofetil.
* Prior treatment for alveolitis with mycophenolate mofetil or prior or current treatment for alveolitis with: D-penicillamine, methotrexate, colchicine, Potaba, or azathioprine.
* Other serious concomitant medical illness (e.g., cancer).
* Forced expiratory volume in 1 second (FEV1)/FVC ratio \< 65%.
* If of childbearing potential, failure regularly to be employing two reliable means of contraception (i.e., condom, abstinence, intrauterine device (IUD), tubal ligation, vasectomy)
* Pulmonary hypertension (defined as an estimated systolic blood pressure (SBP) ≥ 35 mmHg measured by echocardiogram).
* Smoking of cigars, pipes, or cigarettes during the past 6 months.
* Clinically significant abnormalities on chest x-ray or HRCT scan other than interstitial lung disease (e.g., lung mass, evidence of active pulmonary infection).
* Use of prednisone (or equivalent) in doses \> 10 mg per day.
* Does not have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils on screening BAL fluid and does not have ground glass opacification on HRCT.
* Unable to take oral medication.
* Not able to comply with study procedures in the opinion of the investigator.

Primary outcomes:
measure: Mean Change From Baseline in Forced Vital Capacity (FVC)
timeFrame: Baseline, 12 months
Secondary outcomes:
measure: Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils)
timeFrame: Baseline, 12 months
measure: Change in Shortness of Breath (Self-reported)
timeFrame: Baseline, 12 months
measure: Mean Change in Six Minute Walk Distance
timeFrame: 12 months
measure: Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
timeFrame: 12 months
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF, 400 Parnassus Ave
state: California
Study officials:
affiliation: University of California, San Francisco
name: Jeffrey A Golden, MD
role: PRINCIPAL_INVESTIGATOR
References: